Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.

Annals of neurology - 1 Jan 2003

DeKosky Steven T, Ikonomovic Milos D, Wang Xiaoyan, Farlow Martin, Wisniewski Stephen, Lopez Oscar L, Becker James T, Saxton Judith, Klunk William E, Sweet Robert, Kaufer Daniel I, Kamboh M Ilyas

Abstract excerpt

alpha-1-Antichymotrypsin (ACT) is present in neuritic plaques in which it participates in the inflammatory cascade of Alzheimer's disease (AD). Reports of blood ACT levels in AD, and its usefulness as a disease biomarker, have been conflicting. In an effort to clarify this, we measured plasma ACT levels in 516 white subjects including 359 subjects with probable or possible AD, 44 subjects with other late-life...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to alpha 1-Antichymotrypsin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alzheimer Disease

Share to Apolipoproteins E

Share to Biomarkers

Share to Cognition Disorders

Share to Genotype

Source

Identifiers

PMID: 12509851
DOI: 10.1002/ana.10414

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.PMID 12509851Read ↗

Blood levels of alpha-1-antichymotrypsin and risk factors for Alzheimer's disease: effects of gender and apolipoprotein E genotype.Semantic proximity Read ↗

Plasma alpha1-antichymotrypsin in Alzheimer's disease; relationships with APOE genotypes.Semantic proximity Read ↗

Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: a potential therapeutic target.Semantic proximity Read ↗

Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease.Semantic proximity Read ↗

Post-stroke dementia is associated with alpha(1)-antichymotrypsin polymorphism.Semantic proximity Read ↗

A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease.Semantic proximity Read ↗

Distribution of plasma alpha 1-antichymotrypsin levels in Alzheimer disease patients and controls and their genetic controls.Semantic proximity Read ↗

Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk.Semantic proximity Read ↗

Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype.Semantic proximity Read ↗

APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism.Semantic proximity Read ↗

Alpha-1-antichymotrypsin polymorphism in schizophrenia: frequency, age at onset and cognitive function.Semantic proximity Read ↗

No association between alpha-1-antichymotrypsin polymorphism and Alzheimer's disease in Chinese.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.